Coexistence of Sarcoidosis and Hypersensitivity Pneumonitis: Diagnostic and Treatment Specificities

The coexistence of sarcoidosis and hypersensitivity pneumonitis (HP) has been described, suggesting a common pathogenic context. <bold>Methods:</bold> Retrospective analysis, through the review of medical records, of patients with sarcoidosis and HP of a tertiary hospital. <bold>Results:</bold> Five Caucasian patients, predominantly male (n=4) and with a recognized antigenic exposure (80%). One patient had an initial diagnosis of HP, two of sarcoidosis, and the other two both conditions simultaneously. The median time difference between the sequential diagnoses was 6 years. Upon diagnosis, patients exhibited respiratory symptoms, restrictive syndrome and reduced carbon monoxide diffusing capacity. Prevalent imaging pattern comprised micronodular (perilymphatic and/or centrilobular) features alongside mediastinal adenopathies (n=3). All patients underwent lung biopsy for diagnostic confirmation. Antigen avoidance was recommended to all patients upon HP diagnosis. Immunosuppressive treatment was managed according to the most active disease with the prescription of various drugs during follow-up. All patients were treated with corticosteroids. The patient diagnosed initially with PH and then sarcoidosis was also treated with methotrexate followed by azathioprine and then rituximab (due to intolerance and disease progression). In the instances of concurrent sarcoidosis and PH it was also necessary to switch the drugs, for instance for cyclophosphamide and then mycophenolate mofetil. Two patients deceased, 11 and 14 years post-second diagnosis. <bold>Conclusions:</bold> The coexistence of sarcoidosis and HP underscores the complexity and necessity of dynamic therapeutic management, tailored to the predominant evolving disease.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.2168
Primary Topic
Sarcoidosis and Beryllium Toxicity Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Coexistence of Sarcoidosis and Hypersensitivity Pneumonitis: Diagnostic and Treatment Specificities

Conceição Souto Moura, André Carvalho, David Barros Coelho, Natália Melo et al.
Sarcoidosis and Beryllium Toxicity Research
article

Coexistence of Sarcoidosis and Hypersensitivity Pneumonitis: Diagnostic and Treatment Specificities

Conceição Souto Moura, André Carvalho, David Barros Coelho, Natália Melo, Patrícia Caetano Mota, António Morais, H Novais Bastos, André Terras, Susana Guimarães, MLRO Almeida
article en

Abstract

The coexistence of sarcoidosis and hypersensitivity pneumonitis (HP) has been described, suggesting a common pathogenic context. <bold>Methods:</bold> Retrospective analysis, through the review of medical records, of patients with sarcoidosis and HP of a tertiary hospital. <bold>Results:</bold> Five Caucasian patients, predominantly male (n=4) and with a recognized antigenic exposure (80%). One patient had an initial diagnosis of HP, two of sarcoidosis, and the other two both conditions simultaneously. The median time difference between the sequential diagnoses was 6 years. Upon diagnosis, patients exhibited respiratory symptoms, restrictive syndrome and reduced carbon monoxide diffusing capacity. Prevalent imaging pattern comprised micronodular (perilymphatic and/or centrilobular) features alongside mediastinal adenopathies (n=3). All patients underwent lung biopsy for diagnostic confirmation. Antigen avoidance was recommended to all patients upon HP diagnosis. Immunosuppressive treatment was managed according to the most active disease with the prescription of various drugs during follow-up. All patients were treated with corticosteroids. The patient diagnosed initially with PH and then sarcoidosis was also treated with methotrexate followed by azathioprine and then rituximab (due to intolerance and disease progression). In the instances of concurrent sarcoidosis and PH it was also necessary to switch the drugs, for instance for cyclophosphamide and then mycophenolate mofetil. Two patients deceased, 11 and 14 years post-second diagnosis. <bold>Conclusions:</bold> The coexistence of sarcoidosis and HP underscores the complexity and necessity of dynamic therapeutic management, tailored to the predominant evolving disease.

Hospital de São João (PT), Administração Regional de Saúde de Lisboa e Vale do Tejo (PT), Câmara Municipal de Almada (PT)
Openalex Percentile: Top 72%
Sarcoidosis and Beryllium Toxicity Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.